Better Health for All

Repare Therapeutics is a clinical-stage precision oncology company focused entirely on developing novel therapeutics for various cancers, indicating that 100% of its business is devoted to health improvement.

Early clinical trial results for Lunresertib and Camonsertib show a 25.9% overall response rate in endometrial cancer patients and 37.5% in platinum-resistant ovarian cancer patients, with nearly half of patients maintaining progression-free survival at 24 weeks, comparing favorably to the standard of care. The company's business model is inherently health-positive, with no revenue from harmful products. Repare Therapeutics' net R&D expenses were $115.9 million for the twelve-month period ended December 31, 2024, and $133.6 million for the twelve-month period ended December 31, 2023, demonstrating a significant investment in health innovation. The company conducts its clinical trials in accordance with Good Clinical Practice (GCP) requirements, with independent review board (IRB) approval and informed consent, and has consulted with the U.S. FDA and European Medicines Agency on its registrational development plans.

Fair Pay & Worker Respect

Repare Therapeutics Inc. employees rate the company 4.8 out of 5 stars based on 22 Glassdoor reviews.

Furthermore, 100% of employees would recommend working there, and 100% of job seekers rate their interview experience positively. This indicates a high level of employee engagement and satisfaction.

Fair Trade & Ethical Sourcing

No incidents of forced or child labour were identified for the financial year ended December 31, 2023, as reported on May 7, 2024, under Canada’s Fighting Against Forced Labour and Child Labour in Supply Chains Act.

The company requires new suppliers to certify compliance with its Supplier Code of Conduct, which addresses human trafficking, modern slavery, and child labour, and incorporates this compliance into new purchase orders. However, the percentage of all supplier contracts that include enforceable ethical-sourcing clauses is not specified, only that it applies to new suppliers and new purchase orders.

Kind to Animals

Repare Therapeutics has a policy, effective February 27, 2024, stating that all animal research, whether internal or by partners, adheres to industry and government standards, ensuring appropriate care and minimizing pain and stress for animals.

The company uses animals such as mice, rats, and non-human primates in various animal models for preclinical evaluations. For RP-1664, preclinical in vivo animal model evaluations were performed both internally and in collaboration with Children’s Hospital of Philadelphia.

Planet-Friendly Business

No data related to environmental, social, or governance (ESG) metrics, sustainability targets, or planet-friendly business practices is present in the provided articles for Repare Therapeutics Inc.

Therefore, no KPIs can be scored against the 'Planet-Friendly Business' value.

Respect for Cultures & Communities

Repare Therapeutics has implemented a whistleblowing policy and provides a toll-free compliance hotline and an external website for reporting concerns.

All employees are required to complete annual training on the Code of Business Conduct and Ethics, which incorporates awareness of modern slavery, including forced labor and child labor.